Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Conference Call November 15, 2023 4:30 PM ET

Company Participants

Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations, Marketing

Joseph Payne - President and Chief Executive Officer

Andrew Sassine - Chief Financial Officer

Padmanabh Chivukula - Chief Scientific Officer and Chief Operating Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Myles Minter - William Blair

Seamus Fernandez - Guggenheim

Carly Kenselaar - Citi

Pete Stavropoulos - Cantor Fitzgerald

Thomas Yip - H.C. Wainwright

Yale Jen - Laidlaw and Company

Operator

Greetings and welcome to the Arcturus Therapeutics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. Thank you. You may proceed.

Neda Safarzadeh

Thank you, operator. Good afternoon and welcome to Arcturus Therapeutics Third Quarter 2023 Financial Update and Pipeline Progress Call. Today's call will be led by Joe Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO, will join them for the Q&A session.

Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statements. Please see the forward-looking statement disclaimer on the Company's press release issued earlier today, as well as the risk factors section in our most recent Form 10-K and in subsequent filings with the SEC.

In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements.

And with that, I will now turn the call over to Joe.

Joseph Payne

Thank you, Neda. It's good to be with you again, everybody. I'm going to begin my remarks with an update on progress regarding our monovalent COVID-19 vaccine, ARCT-154, following favorable clinical results from the Phase 3 pivotal studies, the new drug application is currently under review by Japan's Pharmaceuticals and Medical Devices Agency or the PMDA.